Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome

Maturitas

Volumn 77, Issue 4, 2014, Pages 370-374

  Chedraui, Peter ^a   Escobar, Gustavo S ^a   Pérez López, Faustino R ^b   Palla, Giulia ^c   Montt Guevara, Magdalena ^c   Cecchi, Elena ^c   Genazzani, Andrea R ^c   Simoncini, Tommaso ^c  

^a UNIVERSIDAD CATÓLICA DE SANTIAGO DE GUAYAQUIL   (Ecuador)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Angiogenesis; Cytokines; Growth factors; Inflammation; Metabolic syndrome; Postmenopause

Indexed keywords

ANGIOPOIETIN 2; CD40 LIGAND; FAS LIGAND; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOLUBLE CD40 LIGAND; SOLUBLE FAS LIGAND; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE; ANGPT2 PROTEIN, HUMAN; FASLG PROTEIN, HUMAN;

ABDOMINAL OBESITY; ADULT; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL FUNCTION; ENDOTHELIUM; ENZYME BLOOD LEVEL; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ADULT; ANGIOPOIETIN-2; CD40 LIGAND; ENDOTHELIUM; FAS LIGAND PROTEIN; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; LINEAR MODELS; METABOLIC SYNDROME X; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; TUMOR NECROSIS FACTOR-ALPHA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84896396182     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.01.014     Document Type: Article

References (41)

1. B. Isomaa, P. Almgren, and T. Tuomi et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683 689
2. S.M. Grundy Metabolic syndrome pandemic Arterioscler Thromb Vasc Biol 28 2008 62936
3. K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano Metabolic syndrome and risk of cancer: a systematic review and meta-analysis Diabetes Care 35 2012 2402 2411
4. D.W. Dunstan, P.Z. Zimmet, and T.A. Welborn et al. Australian Diabetes, Obesity and Lifestyle Study (AusDiab). The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study Diabetes Care 25 2002 829 834
5. A. Whaley-Connell, and J.R. Sowers Indices of obesity and cardiometabolic risk Hypertension 58 2011 991 993
6. P. Chedraui, G. San Miguel, and D. Villacreses et al. Research Group for the Omega Women's Health Project. Assessment of insomnia and related risk factors in postmenopausal women screened for the metabolic syndrome Maturitas 74 2013 154 159
7. S.M. Grundy, J.I. Cleeman, and S.R. Daniels et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2005 2735 2752
8. B. Houser Bio-Rad's Bio-Plex(R) suspension array system, xMAP technology overview Arch Physiol Biochem 118 2012 192 196
9. P. Tighe, O. Negm, I. Todd, and L. Fairclough Utility, reliability and reproducibility of immunoassay multiplex kits Methods 61 2013 23 29
10. Y.W. Chen, H.B. Pan, H.H. Tseng, Y.T. Hung, J.S. Huang, and C.P. Chou Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors Int J Mol Sci 14 2013 17536 17552
11. Y. Wei, G. Liu, J. Yang, R. Zheng, L. Jiang, and P. Bao The association between metabolic syndrome and vascular endothelial dysfunction in adolescents Exp Ther Med 5 2013 1663 1666
12. P. Chedraui, W. Jaramillo, F.R. Pérez-López, G.S. Escobar, N. Morocho, and L. Hidalgo Pro-inflammatory cytokine levels in postmenopausal women with the metabolic syndrome Gynecol Endocrinol 27 2011 685 691
13. K. Indulekha, J. Surendar, and V. Mohan High sensitivity C-reactive protein, tumor necrosis factor-α, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105) J Diabetes Sci Technol 5 2011 982 988
14. K. Eder, N. Baffy, A. Falus, and A.K. Fulop The major inflammatory mediator interleukin-6 and obesity Inflamm Res 58 2009 727 736
15. M.E. Piché, S. Lemieux, S.J. Weisnagel, L. Corneau, A. Nadeau, and J. Bergeron Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women Am J Cardiol 96 2005 92 97
16. D.M. Tehrani, J.M. Gardin, and D. Yanez et al. Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: Cardiovascular Health Study Atherosclerosis 231 2013 246 251
17. A. Cartier, I. Lemieux, N. Almeras, A. Tremblay, J. Bergeron, and J.P. Després Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-α in men J Clin Endocrinol Metab 93 2008 1931 1938
18. C.Q. Jiang, T.H. Lam, and B. Liu et al. Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD Obesity (Silver Spring) 18 2010 1969 1974
19. F. Blasi, J.D. Vassalli, and K. Dano Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors J Cell Biol 104 1987 801 804
20. M.R. Gyetko, E.A. Libre, J.A. Fuller, G.H. Chen, and G. Toews Urokinase is required for T lymphocyte proliferation and activation in vitro J Lab Clin Med 133 1999 274 288
21. F. Blasi, and P. Carmeliet uPAR: a versatile signalling orchestrator Nat Rev Mol Cell Biol 3 2002 932 943
22. F. Blasi uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18 1997 415 417
23. L. Ossowski, and J.A. Aguirre-Ghiso Urokinase receptor and integrin partnership: coordination of signalling for cell adhesion, migration and growth Curr Opin Cell Biol 12 2000 613 620
24. D.E. Vaughan PAI-1 and cellular migration: dabbling in paradox Arterioscler Thromb Vasc Biol 22 2002 1522 1523
25. G. Buchwalter, C. Gross, and B. Wasylyk The ternary complex factor Net regulates cell migration through inhibition of PAI-1 expression Mol Cell Biol 25 2005 10853 10862
26. P.J. Declerck, and A. Gils Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin Semin Thromb Hemost 39 2013 356 364
27. H.C. Chung, S.Y. Rha, and J.O. Park et al. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients Breast Cancer Res Treat 49 1998 41 50
28. K.K. Koh, R. Mincemoyer, and M.N. Bui et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women N Engl J Med 336 1997 683 690
29. K.K. Koh, M.-S. Shin, and I. Sakuma et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women Arterioscler Thromb Vasc Biol 24 2004 1516 1521
30. L. Goglia, V. Tosi, A.M. Sanchez, M.I. Flamini, X.D. Fu, and S. Zullino et al. Endothelial regulation of eNOS, PAI-1 and t-PA by testosterone and dihydrotestosterone in vitro and in vivo Mol Hum Reprod 16 2010 761 769
31. A. San Miguel Hernández, L. Inglada-Galiana, R. García Iglesias, N. Alonso Castillejos, and F.J. Martín Gil Soluble CD40 ligand: a potential marker of cardiovascular risk Rev Clin Esp 207 2007 418 421
32. C. Antoniades, C. Bakogiannis, D. Tousoulis, A.S. Antonopoulos, and C. Stefanadis The CD40/CD40 ligand system: linking inflammation with atherothrombosis J Am Coll Cardiol 54 2009 669 677
33. J.M. Gómez, R. Vila, P. Catalina, J. Soler, L. Badimón, and M. Sah The markers of inflammation and endothelial dysfunction in correlation with glycated haemoglobin are present in type 2 diabetes mellitus patients but not in their relatives Glycoconj J 25 2008 573 579
34. I.G. Palomo, J.C. Jaramillo, and M.L. Alarcón et al. Increased concentrations of soluble vascular cell adhesionmolecule-1 and soluble CD40L in subjects with metabolic syndrome Mol Med Rep 2 2009 481 485
35. B. Gustafson Adipose tissue, inflammation and atherosclerosis J Atheroscler Thromb 17 2010 332 341
36. H.S. Lim, A.D. Blann, and G.Y. Lip Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention Circulation 109 2004 2524 2528
37. A. Onat, G. Can, H. Kaya, and G. Hergenç Atherogenic index of plasma (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events J Clin Lipidol 4 2010 89 98
38. A. Onat Metabolic syndrome: nature, therapeutic solutions and options Expert Opin Pharmacother 12 2011 1887 1900
39. A. Onat, G. Can, E. Örnek, V. Sansoy, M. AydIn, and H. Yüksel Abdominal obesity with hypertriglyceridaemia, lipoprotein(a) and apolipoprotein A-I determine marked cardiometabolic risk Eur J Clin Invest 43 2013 1129 1139
40. F.R. Pérez-López, P. Chedraui, J. Haya, and J.L. Cuadros Effects of the Mediterranean diet on longevity and age-related morbid conditions Maturitas 64 2009 67 79
41. P. Chedraui, and F.R. Pérez-López Nutrition and health during mid-life: searching for solutions and meeting challenges for the aging population Climacteric 16 Suppl. 1 2013 85 95